REGENERON PHARMACEUTICALS, INC.

REGN 10-Q · Q2 2025
API behind this page

REGN Q2 2025 request

Playground key active
Request URL /api/financials?ticker=REGN&year=2025&quarter=2
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q2 2025 Q2 2024 YoY
Revenue 3,675.6 3,547.1 +3.6%
Show Product Lines breakouts
Collaboration revenue 1,860.7 1,524 +22.1%
ELYEA HD And EYLEA · US 1,147.5 1,534.7 -25.2%
ELYEA HD · US 393.2 304.2 +29.3%
Evkeeza · US 41.2 30.4 +35.5%
EYLEA · US 754.3 1,230.5 -38.7%
Libtayo 376.5 297.4 +26.6%
Libtayo · Non Us 128.7 115 +11.9%
Libtayo · US 247.8 182.4 +35.9%
Praluent · US 65.8 56.1 +17.3%
Product 1,631 1,918.6 -15.0%
Product And Service Other 183.9 104.5 +76.0%
Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses · Non Us -5.6 -14.7 +61.9%
Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses · Sanofi Collaboration Agreement, Antibody -18 -9.1 -97.8%
Regeneron's share of profits · Non Us 383.4 353 +8.6%
Regeneron's share of profits · Sanofi Collaboration Agreement, Antibody 1,282.1 988.3 +29.7%
Reimbursement for manufacturing of commercial supplies · Non Us 31.6 22.1 +43.0%
Reimbursement for manufacturing of commercial supplies · Sanofi Collaboration Agreement, Antibody 161.5 157.3 +2.7%
Reimbursement of commercialization-related expenses · Sanofi Collaboration Agreement, Antibody 194 150.8 +28.6%
Research & Development 1,421.7 1,200 +18.5%
Show Business Segments breakouts
Reportable Segment 1,421.7 1,200 +18.5%
Reportable Segment · Clinical manufacturing costs 337 260.1 +29.6%
Reportable Segment · Direct research and development expenses 454.1 363.9 +24.8%
Reportable Segment · Indirect research and development expenses: 64.9 56.5 +14.9%
Reportable Segment · Indirect research and development expenses: 158.6 141.6 +12.0%
Reportable Segment · Indirect research and development expenses: 449.4 422.5 +6.4%
Reportable Segment · Indirect research and development expenses: 672.9 620.6 +8.4%
Acquired In Process Research And Development 10 23.9 -58.2%
Selling, General & Administrative 634.2 758.8 -16.4%
Cost of Revenue (Q) — — —
Show Product Lines breakouts
Cost of collaboration and contract manufacturing 254.6 222.4 +14.5%
Product 275.6 257.8 +6.9%
Total Costs & Expenses 2,596.1 2,477.5 +4.8%
Operating Income 1,079.5 1,069.6 +0.9%
Other Non-Operating Income (Expense) 442.8 573.3 -22.8%
Interest Expense -3.6 -14.8 +75.7%
Non-Operating Income (Expense) 439.2 558.5 -21.4%
Income Before Taxes 1,518.7 1,628.1 -6.7%
Income Tax Expense (Benefit) 127.1 195.8 -35.1%
Net Income 1,391.6 1,432.3 -2.8%
Show Equity Components breakouts
Retained Earnings 1,391.6 1,432.3 -2.8%
EPS (Basic) 13.24 13.25 -0.1%
EPS (Diluted) 12.81 12.41 +3.2%
Wtd Avg Shares (Basic) 105.1 108.1 -2.8%
Wtd Avg Shares (Diluted) 108.6 115.4 -5.9%
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 22.1 7.9 +179.7%
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent 1.3 -0.6 +316.7%
Comprehensive Income 1,415 1,439.6 -1.7%
Other Comprehensive Income 23.4 7.3 +220.5%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 23.4 7.3 +220.5%

Balance Sheet

Balance Sheet
Metric Q2 2025 Q2 2024 YoY
Current Assets
Cash & Cash Equivalents 1,995.8 1,920.7 +3.9%
Marketable Securities (Current) 5,473.8 7,888.3 -30.6%
Accounts Receivable 5,610 5,717.1 -1.9%
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts
Trade Accounts Receivable 3.58 3.96 -9.5%
Show Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project breakouts
Bayer 388.2 373.4 +4.0%
Sanofi Collaboration Agreement, Antibody 1,336.8 1,133 +18.0%
Inventory 3,205.6 2,873.6 +11.6%
Prepaid Expenses & Other Current Assets 574.3 681.9 -15.8%
Total Current Assets 16,859.5 19,081.6 -11.6%
Non-Current Assets
Marketable Securities (Non-Current) 10,058.2 7,722.4 +30.2%
Deferred Tax Assets 3,572.2 2,880.9 +24.0%
Other Non-Current Assets 1,536.9 993.8 +54.6%
Total Assets 38,219.2 36,086.8 +5.9%
Other Assets
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization 4,840.7 4,305.9 +12.4%
Intangible Assets Net Excluding Goodwill 1,351.7 1,102.2 +22.6%
Current Liabilities
Accounts Payable 723.9 561.7 +28.9%
Accrued Liabilities And Other Liabilities 2,461.2 2,360.9 +4.2%
Deferred Revenue (Current) 481.9 586 -17.8%
Total Current Liabilities 3,667 3,508.6 +4.5%
Non-Current Liabilities
Long-Term Debt 1,985.1 1,983.6 +0.1%
Finance Lease Liability Noncurrent 720 720 0.0%
Contract With Customer Liability Noncurrent 206.3 205.6 +0.3%
Other Non-Current Liabilities 1,701.9 1,463.2 +16.3%
Total Liabilities 8,280.3 7,881 +5.1%
Stockholders' Equity
Common Stock (Q) — — —
Show Statement Class Of Stock breakouts
Common Stock 0.1 0.1 0.0%
Additional Paid-In Capital 13,490.8 12,316.9 +9.5%
Retained Earnings 33,680.2 29,414.6 +14.5%
Accumulated Other Comprehensive Income 52.5 -69.9 +175.1%
Treasury Stock Common Value -17,284.7 -13,455.9 -28.5%
Total Stockholders' Equity 29,938.9 28,205.8 +6.1%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 52.5 -69.9 +175.1%
Additional Paid In Capital 13,490.8 12,316.9 +9.5%
Common Stock 0.1 0.1 0.0%
Retained Earnings 33,680.2 29,414.6 +14.5%
Treasury Stock Common -17,284.7 -13,455.9 -28.5%
Total Liabilities & Equity 38,219.2 36,086.8 +5.9%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q2 2025 YTD Q2 2024 YoY
Operating Activities
Depreciation & Amortization 262 234.8 +11.6%
Stock-Based Compensation 507.4 453.3 +11.9%
Marketable And Other Securities Gain Loss -389.9 -196.5 -98.4%
Other Non-Cash Items -17.7 -2.9 -510.3%
Increase Decrease In Deferred Income Taxes -274.3 -308.5 +11.1%
Change in Accounts Receivable 629.6 -47.3 +1431.1%
Change in Inventory -194.8 -337.6 +42.3%
Change in Prepaid & Other Assets -410.2 -604.2 +32.1%
Change in Deferred Revenue -125.2 206 -160.8%
Increase Decrease In Accounts Payable And Accrued Liabilities 2.3 315.1 -99.3%
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities -10.8 -287.8 +96.2%
Net Cash from Operations 2,189.5 1,866.5 +17.3%
Investing Activities
Payments To Acquire Marketable Securities -5,394.4 -10,073.4 +46.4%
Proceeds From Sale And Maturity Of Marketable Securities 5,626.2 8,186.7 -31.3%
Payments To Acquire Productive Assets -448.3 -314.4 -42.6%
Payments To Acquire Intangible Assets1 -230 -58.3 -294.5%
Net Cash from Investing -446.5 -2,244.3 +80.1%
Financing Activities
Proceeds From Issuance Of Common Stock 92.1 1,119.7 -91.8%
Tax Withholding for Share Compensation -9.9 -655.5 +98.5%
Share Repurchases -2,102.9 -895.2 -134.9%
Payments Of Dividends -186.4 — —
Proceeds From Payments For Other Financing Activities -10.3 — —
Net Cash from Financing -2,217.4 -431 -414.5%
Supplemental
Unpaid Capital Expenditures 126.1 112.6 +12.0%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1 -0.8 +225.0%
Net Change in Cash -473.4 -809.6 +41.5%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 2,015.6 1,928.2 +4.5%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key